Google
ACAD 株価分析 — Acadia Pharmaceuticals Inc (Healthcare >> Biotechnology)
ACAD に関するよくある質問
ACADのPER（株価収益率）は？
Acadia Pharmaceuticals Inc（ACAD）は現在PER 11.79倍で取引されています。
ACADのROE（自己資本利益率）は？
Acadia Pharmaceuticals IncのROEは30.10%です。
ACADの配当利回りは？
Acadia Pharmaceuticals Incの配当利回りは0.00%です。
ACADの品質スコア（Quality Score）は？
当社のAIはACADの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ACADは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ACADはどのセクターに属しますか？
Acadia Pharmaceuticals IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
ACAD AI Analysis Summary
Our AI summary for ACAD: Acadia Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 11.79, ROE of 30.10%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 25.61
Price
-0.26
(-1.01%)
Day Change
|
|
|---|
ACAD, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
222
|
| Magic Formula Rank by ROE |
222
|
| Magic Formula Rank by ROIC |
397
|
| Price | 25.61 |
| PBV / Sector |
3.55 / 44,219.29
|
| Earning Per Share | 2.17 |
| PE / Sector |
11.79 / 19.28
GOOD
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
35.24 M
GREAT
|
| Average 1W Daily Value |
34.99 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:05 |
| Symbol | ACAD |
| Name | ACADIA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 171.24 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,429.87 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 12830 El Camino Real, San Diego, CA, United States, 92130
Phone: 858 558 2871
Website: https://www.acadia.com
Employees: 796
Sector: Healthcare >> Biotechnology
Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
